Literature DB >> 9811895

Modeling the impact of global tuberculosis control strategies.

C J Murray1, J A Salomon.   

Abstract

An epidemiological model of tuberculosis has been developed and applied to five regions of the world. Globally, 6.7 million new cases of tuberculosis and 2.4 million deaths from tuberculosis are estimated for 1998. Based on current trends in uptake of the World Health Organization's strategy of directly observed treatment, short-course, we expect a total of 225 million new cases and 79 million deaths from tuberculosis between 1998 and 2030. Active case-finding by using mass miniature radiography could save 23 million lives over this period. A single contact treatment for tuberculosis could avert 24 million cases and 11 million deaths; combined with active screening, it could reduce mortality by nearly 40%. A new vaccine with 50% efficacy could lower incidence by 36 million cases and mortality by 9 million deaths. Support for major extensions to global tuberculosis control strategies will occur only if the size of the problem and the potential for action are recognized more widely.

Entities:  

Mesh:

Year:  1998        PMID: 9811895      PMCID: PMC24946          DOI: 10.1073/pnas.95.23.13881

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

2.  Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group.

Authors: 
Journal:  Indian J Lepr       Date:  1997 Apr-Jun

3.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

4.  Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection.

Authors:  P M Small; R W Shafer; P C Hopewell; S P Singh; M J Murphy; E Desmond; M F Sierra; G K Schoolnik
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

5.  Study of case-finding for pulmonary tuberculosis in outpatients complaining of a chronic cough at a district hospital in Kenya.

Authors:  J A Aluoch; O B Swai; E A Edwards; H Stott; J H Darbyshire; W Fox; I Sutherland
Journal:  Am Rev Respir Dis       Date:  1984-06

6.  The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands.

Authors:  I Sutherland; E Svandová; S Radhakrishna
Journal:  Tubercle       Date:  1982-12

7.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Authors:  D E Kopanoff; D E Snider; G J Caras
Journal:  Am Rev Respir Dis       Date:  1978-06

8.  Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration.

Authors: 
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

9.  The intrinsic transmission dynamics of tuberculosis epidemics.

Authors:  S M Blower; A R McLean; T C Porco; P M Small; P C Hopewell; M A Sanchez; A R Moss
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

10.  Tuberculosis in a rural population of South India: a five-year epidemiological study.

Authors: 
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

View more
  79 in total

1.  Criteria for the control of drug-resistant tuberculosis.

Authors:  C Dye; B G Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Genetic predisposition to clinical tuberculosis: bridging the gap between simple and complex inheritance.

Authors:  L Abel; J L Casanova
Journal:  Am J Hum Genet       Date:  2000-07-05       Impact factor: 11.025

Review 3.  Life and death in a macrophage: role of the glyoxylate cycle in virulence.

Authors:  Michael C Lorenz; Gerald R Fink
Journal:  Eukaryot Cell       Date:  2002-10

4.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

5.  A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa.

Authors:  D Guwatudde; S M Debanne; M Diaz; C King; C C Whalen
Journal:  Prev Med       Date:  2004-11       Impact factor: 4.018

6.  Adenylyl cyclase Rv1625c of Mycobacterium tuberculosis: a progenitor of mammalian adenylyl cyclases.

Authors:  Y L Guo; T Seebacher; U Kurz; J U Linder; J E Schultz
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

7.  Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission.

Authors:  Ted Cohen; Caroline Colijn; Bryson Finklea; Megan Murray
Journal:  J R Soc Interface       Date:  2007-06-22       Impact factor: 4.118

8.  Crystallization and preliminary X-ray characterization of phosphoglucose isomerase from Mycobacterium tuberculosis H37Rv.

Authors:  Divya Mathur; Kanchan Anand; Deepika Mathur; Nirmala Jagadish; Anil Suri; Lalit C Garg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-03-30

9.  Identifying dynamic tuberculosis case-finding policies for HIV/TB coepidemics.

Authors:  Reza Yaesoubi; Ted Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

10.  Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users.

Authors:  Jonathan E Golub; Jacquie Astemborski; Mohammed Ahmed; Wendy Cronin; Shruti H Mehta; Gregory D Kirk; David Vlahov; Richard E Chaisson
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.